Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients with Moderately Low Protein Diet
2024-516764-29-00Phase 3Authorised
- Sponsor
- CHU Gabriel-Montpied
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of Ketosteril in chronic kidney disease (CKD), sponsored by CHU Gabriel-Montpied. Primary endpoint: Muscle mass index at 12 months. Planned start Jan 2025; status: authorised.
02
Drugs
Ketosteril
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-516764-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516764-29-00.